Implementation of proteomic biomarkers: making it work

نویسندگان

  • Harald Mischak
  • John PA Ioannidis
  • Angel Argiles
  • Teresa K Attwood
  • Erik Bongcam-Rudloff
  • Mark Broenstrup
  • Aristidis Charonis
  • George P Chrousos
  • Christian Delles
  • Anna Dominiczak
  • Tomasz Dylag
  • Jochen Ehrich
  • Jesus Egido
  • Peter Findeisen
  • Joachim Jankowski
  • Robert W Johnson
  • Bruce A Julien
  • Tim Lankisch
  • Hing Y Leung
  • David Maahs
  • Fulvio Magni
  • Michael P Manns
  • Efthymios Manolis
  • Gert Mayer
  • Gerjan Navis
  • Jan Novak
  • Alberto Ortiz
  • Frederik Persson
  • Karlheinz Peter
  • Hans H Riese
  • Peter Rossing
  • Naveed Sattar
  • Goce Spasovski
  • Visith Thongboonkerd
  • Raymond Vanholder
  • Joost P Schanstra
  • Antonia Vlahou
چکیده

While large numbers of proteomic biomarkers have been described, they are generally not implemented in medical practice. We have investigated the reasons for this shortcoming, focusing on hurdles downstream of biomarker verification, and describe major obstacles and possible solutions to ease valid biomarker implementation. Some of the problems lie in suboptimal biomarker discovery and validation, especially lack of validated platforms with well-described performance characteristics to support biomarker qualification. These issues have been acknowledged and are being addressed, raising the hope that valid biomarkers may start accumulating in the foreseeable future. However, successful biomarker discovery and qualification alone does not suffice for successful implementation. Additional challenges include, among others, limited access to appropriate specimens and insufficient funding, the need to validate new biomarker utility in interventional trials, and large communication gaps between the parties involved in implementation. To address this problem, we propose an implementation roadmap. The implementation effort needs to involve a wide variety of stakeholders (clinicians, statisticians, health economists, and representatives of patient groups, health insurance, pharmaceutical companies, biobanks, and regulatory agencies). Knowledgeable panels with adequate representation of all these stakeholders may facilitate biomarker evaluation and guide implementation for the specific context of use. This approach may avoid unwarranted delays or failure to implement potentially useful biomarkers, and may expedite meaningful contributions of the biomarker community to healthcare.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Proteomic Analysis of Gene Expression in Basal Cell Carcinoma

Background: Basal Cell Carcinoma (BCC) is a type of non-melanoma skin cancer. Alteration in gene expression is the important event that happens in cancer cell. Detection of this event is possible by proteomics techniques. Methods: Normal and tumor tissues were taken from BCC patient. Total proteins were purified by standard methods, and proteins were separated by two-dimensional electrophoresis...

متن کامل

Clinical Significance of Salivary Biomarkers in Oral Squamous Cell Carcinoma: A Review

Background and Aim: Oral squamous cell carcinoma (OSCC) accounts for approximately 3% of all cancers worldwide, and if diagnosed early, it has a five-year survival rate of around 85%; however, a late diagnosis may decrease the survival rate to 50%. Aberrant expression of several genes is associated with the hallmarks of OSCC including uncontrolled cell proliferation, poor differentiation, invas...

متن کامل

A New Hybrid Feature Subset Selection Algorithm for the Analysis of Ovarian Cancer Data Using Laser Mass Spectrum

Introduction: Amajor problem in the treatment of cancer is the lack of an appropriate method for the early diagnosis of the disease. The chemical reaction within an organ may be reflected in the form of proteomic patterns in the serum, sputum, or urine. Laser mass spectrometry is a valuable tool for extracting the proteomic patterns from biological samples. A major challenge in extracting such ...

متن کامل

A Supply - Scarcity and Strategic Decision-Making Angle: High Performance Work Practices in Small Firms

High performance work practices (HPWPs) are human resource management practices aimed at stimulating employee and organisational performance. The application of HPWPs is not widespread in small organisations. We examine whether the implementation of coherent bundles of HPWPs (aimed at employee ability, employee motivation or at the opportunity to perform) depends on the scarcity of resources, a...

متن کامل

Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development

Biomarker research is continuously expanding in the field of clinical proteomics. A combination of different proteomic-based methodologies can be applied depending on the specific clinical context of use. Moreover, current advancements in proteomic analytical platforms are leading to an expansion of biomarker candidates that can be identified. Specifically, mass spectrometric techniques could p...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 42  شماره 

صفحات  -

تاریخ انتشار 2012